[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018000947A - Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2. - Google Patents

Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2.

Info

Publication number
MX2018000947A
MX2018000947A MX2018000947A MX2018000947A MX2018000947A MX 2018000947 A MX2018000947 A MX 2018000947A MX 2018000947 A MX2018000947 A MX 2018000947A MX 2018000947 A MX2018000947 A MX 2018000947A MX 2018000947 A MX2018000947 A MX 2018000947A
Authority
MX
Mexico
Prior art keywords
crth2 receptor
response
genetic markers
receptor antagonists
markers associated
Prior art date
Application number
MX2018000947A
Other languages
English (en)
Inventor
J Opiteck Gregory
H Wong Peggy
Mcelwee Joshua
V Mehrotra Devan
Greenberg Steven
Guo Zifang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2018000947A publication Critical patent/MX2018000947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención provee marcadores genéticos en el cromosoma 1 humano que están asociados con una respuesta benéfica a los antagonistas del receptor CRTH2; estos marcadores de respuesta al antagonista del receptor CRTH2 son útiles, entre otras cosas, para identificar a los pacientes que es más probable que se beneficien del tratamiento con composiciones y productos farmacéuticos del antagonista del receptor CRTH2, en métodos de tratamiento de pacientes que tienen una enfermedad susceptible al tratamiento con un antagonista del receptor CRTH2, y en métodos para seleccionar la terapia más apropiada para dichos pacientes.
MX2018000947A 2015-07-23 2016-07-21 Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2. MX2018000947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196128P 2015-07-23 2015-07-23
PCT/US2016/043234 WO2017015418A1 (en) 2015-07-23 2016-07-21 Genetic markers associated with response to crth2 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2018000947A true MX2018000947A (es) 2018-06-07

Family

ID=57834578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000947A MX2018000947A (es) 2015-07-23 2016-07-21 Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2.

Country Status (11)

Country Link
US (2) US11091806B2 (es)
EP (1) EP3337803B1 (es)
JP (1) JP6703090B2 (es)
KR (1) KR20180033235A (es)
CN (1) CN107849041B (es)
AU (1) AU2016297005A1 (es)
BR (1) BR112018001267A2 (es)
CA (1) CA2992987A1 (es)
MX (1) MX2018000947A (es)
RU (1) RU2018106032A (es)
WO (1) WO2017015418A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220259656A1 (en) * 2019-05-03 2022-08-18 Merck Sharp & Dohme Corp. Blood biomarker and genetic markers associated with response to crth2 receptor antagonists
KR20210129539A (ko) 2020-04-20 2021-10-28 장민수 초소형 센서를 이용하는 홀로그램 디스플레이 제어방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
AU656514B2 (en) 1989-02-13 1995-02-09 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
JP2001507921A (ja) 1992-04-27 2001-06-19 トラスティーズ オブ ダートマス カレッジ 生物学的液体中の遺伝子配列の検出
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
WO1997022719A1 (en) 1995-12-18 1997-06-26 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
DE69735112T2 (de) 1996-11-06 2006-09-07 Sequenom, Inc., San Diego Verfahren zur Analyse und Vorrichtung
JP4963139B2 (ja) 1996-11-06 2012-06-27 シークエノム・インコーポレーテツド 固体支持体に核酸を固定化するための組成物および方法
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
CA2724632A1 (en) 2008-05-16 2009-11-19 The Children's Hospital Of Philadelphia Asthma susceptibility loci located at chromosome 1q31 for use in diagnostic and therapeutic methods
SI2401269T1 (sl) 2009-02-24 2014-04-30 Merck Sharp & Dohme Corp. Derivati indola kot crth2 receptorski antagonisti
JP5695385B2 (ja) 2009-10-05 2015-04-01 花王株式会社 毛髪形状感受性遺伝子
AU2012271661B8 (en) 2011-06-17 2016-11-10 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
EP2548876A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2935626A4 (en) * 2012-12-21 2016-07-20 Merck Sharp & Dohme BIOMARKER FOR RESPONSE TO A PSORIASIS TREATMENT
CN104726601A (zh) * 2015-03-31 2015-06-24 常州市第二人民医院 与哮喘发病危险度相关的snp标记及其应用

Also Published As

Publication number Publication date
JP2018520199A (ja) 2018-07-26
US20180237856A1 (en) 2018-08-23
JP6703090B2 (ja) 2020-06-03
EP3337803A4 (en) 2019-04-10
US11091806B2 (en) 2021-08-17
AU2016297005A1 (en) 2018-01-18
CA2992987A1 (en) 2017-01-26
US20210348235A1 (en) 2021-11-11
EP3337803A1 (en) 2018-06-27
WO2017015418A1 (en) 2017-01-26
BR112018001267A2 (pt) 2019-10-22
CN107849041B (zh) 2021-07-23
EP3337803B1 (en) 2022-08-17
RU2018106032A3 (es) 2019-09-30
KR20180033235A (ko) 2018-04-02
CN107849041A (zh) 2018-03-27
RU2018106032A (ru) 2019-08-26

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
MY191357A (en) Sustained-release dosage forms of ruxolitinib
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MY201535A (en) Therapeutic compounds
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2019010982A (es) Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos.
MX2017012720A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MY179783A (en) Substituted bicyclic compounds
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine